Select Revenue HighlightsFull-year 2012 worldwide sales were $47.3 billion, a decrease of 2 percent, which includes a 3 percent negative impact from foreign exchange, compared to full-year 2011. Worldwide sales were $11.7 billion for the fourth quarter of 2012, a decrease of 5 percent, which includes a 2 percent negative impact from foreign exchange compared with the fourth quarter of 2011. Strong sales growth of key products helped offset the impact of the August 2012 loss of market exclusivity for SINGULAIR (montelukast sodium) in the United States. The following table reflects sales of the company's top pharmaceutical products, as well as total sales of animal health and consumer care products.
|$ in millions||Fourth Quarter 2012||Fourth Quarter 2011||Change||Year Ended Dec. 31, 2012||Year Ended Dec. 31, 2011||Change|
|PROQUAD, M-M-R II and VARIVAX||306||276||11%||1,273||1,202||6%|